drugset / Trial / NCT01176552
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This prospective study assesses toxicity and potential efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN) alpha and interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC).
Timeline
- Start
- 2004-05
- Primary completion
- 2008-09
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NG-641 | Unknown | 1e+07 iu | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 1e+06 iu | Intravenous |
| Subject | sargramostim | Protein / enzyme biologic | 1 ug/kg | Subcutaneous |